Watching the Hong Kong stock market these past few days has been really tough. Even blue-chip bank stocks like ICBC still fall on partnership news, showing a real lack of market confidence. In the pharma sector, Akeso's performance has been incredibly strong. I always thought innovative drugs were a slow game, but now they're even managing small gains. On the other hand, Giant Biogene is pulling back, and this wave of the aesthetic medicine concept isn't easy to catch. While Kingboard Laminates remains relatively strong, benefiting from both AI materials and copper prices, it still can't break out. Zhaojin Mining is in an even worse state; with the accident, I really don't dare to touch it, not even the gold rally can save it. For now, the best move is to keep a low profile and not make any rash moves.